Surging demand for weight loss drugs Wegovy and Zepbound from Novo Nordisk (NVO) and Eli Lilly (NYSE:LLY) has fueled concerns ...

A pharmacist warns that off-brand Ozempic, Zepbound, and other weight loss products carry undisclosed risks for consumers.

PBMs are putting weight loss drugs, including Wegovy and Zepbound, on their national formularies, but coverage by plans is ...

Semaglutide — the active ingredient in Ozempic®, Wegovy®, and Rybelsus® — can reduce your appetite and curb food cravings to ...

FDA halts actions on makers of compounded drugs as it reviews decision to remove Eli Lilly's (LLY) weight loss drug ...

If Medicare were to start covering popular weight loss drugs such as Wegovy and Zepbound, it could increase federal spending ...

Click in for more news from The Hill{beacon} Health Care Health Care   The Big Story Rival manufacturers fight for the right to sell weight loss drugsThere’s a new fight brewing between ...

A recent study published by the Journal of the American Medical Association (JAMA) found that patients taking the drugs ...

PS makes wellness more accessible through real-life stories, first-person perspectives, and expert-backed information. Our ...

The FDA updated its database of drugs in shortage to remove tirzepatide, which had sat on that list – along with related ...

A review of the recent evidence suggests that GLP-1 drugs, such as semaglutide, could protect brain health and cognitive ...

The $200B GLP-1 market is set to expand with 16 new obesity drugs launching by 2029, challenging Novo Nordisk and Eli Lilly's dominance while addressing scalability and pricing concerns.